Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:32 PM ET 8-K
Financial Results Vuzix Corp VUZI

Vuzix Financial Results

Vuzix Corporation reported third quarter 2026 financial results, showing a 38% revenue decline to $0.7 million as the company transitions toward an OEM-focused business model. The company reported a net loss of $8.4 million ($0.10 per share) while highlighting progress in its defense business and the launch of its Causeway optical interconnect platform.

Term
Q3 2026

“During the third quarter, Vuzix continued to advance its transition towards a more OEM-focused business built around advanced waveguide technologies, optical engineering and its U.S.-based manufacturing capabilities.”

Paul Travers, President and CEO of Vuzix
4:32 PM ET 10-Q
Financial Results TRex Bio, Inc. TRXB

TRex Bio Q3 2026 Results: Net Loss of $13.2M, Loss Widens

TRex Bio, Inc. is a clinical-stage biopharmaceutical company that has incurred substantial losses since inception and expects these losses to increase as it develops its autoimmune and inflammatory disease product candidates. As of November 5, 2026, the company had 28,788,654 shares of common stock outstanding and is classified as an emerging growth company.

Key figure
Net loss $13.2M
4:32 PM ET Form 4
Insider Buying Babcock & Wilcox Enterprises, Inc. BW

Babcock & Wilcox Enterprises Insider Joseph A. Tato Buys $43.8K of Stock

Joseph A. Tato bought 8,304 shares of Babcock & Wilcox Enterprises, Inc. at $5.27 a share, worth $43.8K in total on Nov 11, 2026. Shares held after the trade: 217,338 (+4.0%).

Value
$43.8K
Shares
8,304
Price
$5.27
Holding change
+4.0%
Trade date
Nov 11, 2026
4:32 PM ET 10-Q
Financial Results CH4 Natural Solutions Corp MTNE

CH4 Natural Solutions Q3 2026 Results: Turns Profitable, Net Income $1.74M

CH4 Natural Solutions Corp reported a net loss of $4.15 million for the nine months ended September 30, 2026, primarily driven by $7.44 million in general and administrative expenses. The company completed its initial public offering in May 2026, resulting in $223.3 million held in a Trust Account and a significant shareholders' deficit of $14.4 million.

Key figure
Net income $1.74M
4:32 PM ET 8-K
Nasdaq/NYSE Compliance Notice Singularity Future Technology Ltd. SGLY

Singularity Future Technology Nasdaq/NYSE Compliance Notice

Singularity Future Technology received a delisting notice from Nasdaq on November 10, 2026, because its stock price remained below the $1.00 minimum bid requirement for 30 consecutive business days. Because the company completed a reverse stock split within the past year, it is ineligible for a standard 180-day grace period and faces immediate suspension unless it successfully appeals to a Nasdaq Hearings Panel. Separately, shareholders approved the future issuance of 250 million shares and approximately 6.9 million warrants at a special meeting.

Counterparty
Nasdaq
4:32 PM ET 10-Q
Financial Results Aperture AC APUR

Aperture AC Q3 2026 Results: Turns Profitable, Net Income $125K

Aperture AC is a shell company that consummated its IPO on May 22, 2026, and has entered into a Business Combination Agreement with Atlantic HPC Group Inc. as of September 10, 2026. As of November 13, 2026, the company reported 10,961,000 Class A and 3,772,603 Class B Ordinary Shares outstanding.

Key figure
Net income $125K
4:32 PM ET 8-K
Financial Results Nuvve Holding Corp. NVVE

Nuvve Holding Financial Results

Nuvve Holding Corp. reported third quarter 2026 revenue of $1.09 million, a 31.9% decrease year-over-year primarily due to lower customer sales orders and shipments. The company reported a cash operating loss of $4.3 million and highlighted the development of its Astrea AI-powered forecasting platform for utilities.

Term
Q3 2026

“As we look out to the next several quarters, we expect to see more developments on our European, Japan and New Mexico stationery battery pipeline projects. We also anticipate improvements in our cash burn resulting from the benefits of lower operating costs compared with last year. In parallel, we are bringing Astrea, our Artificial Intelligence ("AI") AI-powered forecasting and grid decision-support platform, to utilities and electric cooperatives, and we are preparing initial technical evaluations with prospective customers.”

Gregory Poilasne, Chief Executive Officer
4:32 PM ET 8-K
Leadership Change Acurx Pharmaceuticals, Inc. ACXP

Acurx Pharmaceuticals Leadership Change

Joseph C. Scodari, a member of the Board of Directors since 2021, notified Acurx Pharmaceuticals of his intention to retire from the Board effective November 13, 2026. His departure is not due to any disagreement with the company, and he has agreed to continue serving as a corporate advisor following his retirement.

4:32 PM ET 10-K
Financial Results Legato Merger Corp. IV LEGO

Legato Merger Corp. IV FY 2026 Results: Net Income $4.2M

Legato Merger Corp. IV reported net income of $4,202,267 for the fiscal year ended August 31, 2026, primarily driven by $4,897,509 in interest income from its trust account. As a blank check company, it has not yet generated operating revenue and is currently searching for a target business for its initial business combination.

Key figure
Net income $4.2M
4:31 PM ET Form 4
Insider Selling Kite Realty Group Trust KRG

Kite Realty Group Trust Chairman & CEO John A. Kite Sells $890K of Stock

John A. Kite, Chairman & CEO, sold 34,492 shares of Kite Realty Group Trust at $25.81 a share, worth $890K in total on Nov 12, 2026. Shares held after the trade: 19,629 (-63.7%).

Value
$890K
Shares
34,492
Price
$25.81
Role
Chairman & CEO
Holding change
-63.7%
Trade date
Nov 12, 2026
4:31 PM ET Form 4
Insider Selling Spotify Technology S.A. SPOT

Spotify Technology Co-CEO Gustav Soderstrom Sells $12.5M of Stock

Gustav Soderstrom, Co-CEO, sold 20,910 shares of Spotify Technology S.A. at $597.57 to $603.41 a share (average $599.37) in 7 transactions, worth $12.5M in total on Nov 11, 2026. Shares held after the trade: 19,792 (-4.2%).

Value
$12.5M
Shares
20,910
Average price
$599.37
Role
Co-CEO
Holding change
-4.2%
Trade date
Nov 11, 2026
4:31 PM ET 8-K
Capital Raise Callan Jmb Inc. CJMB

Callan Jmb Capital Raise of $1.5M

Callan JMB Inc. entered into a securities purchase agreement for a private placement of 1,363,639 shares of common stock at $1.10 per share, raising approximately $1.5 million in gross proceeds. The offering was led by Chairman and CEO Wayne Williams and other company insiders, with the purchase price representing a premium to the market price. Proceeds will be used for strategic growth initiatives and general corporate purposes.

Value
$1.5M
Counterparty
Wayne Williams

“Our leadership team is putting its own capital to work because we believe in the path ahead. This is a direct expression of our confidence in the Company’s strategy, and our commitment to building value alongside shareholders.”

Wayne Williams, Chief Executive Officer of Callan JMB

“We believe the strongest signal we can send is to invest our own capital at a price that is at a multiple above the current market, but still at what we perceive to be a discount to the true value of our shares. Investing alongside our shareholders demonstrates our confidence in the company.”

Christopher Shields, Interim Chief Financial Officer
4:31 PM ET 8-K
M&A Deal Miluna Acquisition Corp MMTX

Miluna Acquisition M&A Deal with CADV Ventures S.A.

Miluna Acquisition Corp entered into an amendment to its existing business combination agreement with CADV Ventures S.A. and Kukugan Invest. The amendment extends the deal's outside closing date from January 23, 2027, to April 23, 2027, and modifies lock-up requirements for certain advisory firms involved in the transaction.

Counterparty
CADV Ventures S.A.
4:31 PM ET 8-K
Financial Results Indaptus Therapeutics, Inc. INDP

Indaptus Therapeutics Financial Results

Indaptus Therapeutics reported its Q3 2026 financial results, highlighting a cash and short-term investment position of approximately $30.6 million following a $24 million private placement. The company is shifting its strategic focus toward neurotechnology and neural-network-based devices for sleep-related conditions while significantly reducing R&D expenses by 82% year-over-year.

“Our strategic objective is to position Indaptus for its next phase of growth by actively pursuing innovative opportunities with significant long-term potential and expanding the Company’s strategic focus into promising areas of medical innovation. We believe the successful completion of our approximately $24.0 million private placement provides an important foundation to advance this vision, giving us the financial resources and strategic flexibility to explore new opportunities and build long-term shareholder value.”

Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board

“We are particularly excited about the opportunity to explore the potential of an innovative neurotechnology- and neural-network-based device for certain sleep-related conditions. We believe this area represents an intriguing opportunity to investigate novel approaches to addressing unmet needs in sleep-related health. Through early-stage research and preclinical evaluation, we hope to further assess its scientific potential and explore a possible development pathway toward a future FDA submission.”

Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board
4:31 PM ET Form 4
Insider Selling Luckin Coffee Inc. LKNCY

Luckin Coffee CEO Jinyi Guo Sells $7.29M of Stock

Jinyi Guo, CEO, sold 200,000 shares of Luckin Coffee Inc. at $36.44 a share, worth $7.29M in total on Nov 11, 2026. Shares held after the trade: 2,563,000 (-7.2%).

Value
$7.29M
Shares
200,000
Price
$36.44
Role
CEO
Holding change
-7.2%
Trade date
Nov 11, 2026
4:31 PM ET Form 4
Insider Buying Trinity Capital Inc. TRIN

Trinity Capital CEO, President and CIO Kyle Steven Brown Buys $58K of Stock

Kyle Steven Brown, CEO, President and CIO, bought 3,215 shares of Trinity Capital Inc. at $18.04 a share, worth $58K in total on Nov 11, 2026. Shares held after the trade: 654,878 (+0.5%).

Value
$58K
Shares
3,215
Price
$18.04
Role
CEO, President and CIO
Holding change
+0.5%
Trade date
Nov 11, 2026
4:31 PM ET 8-K
Deal Termination WinVest Acquisition Corp. WINV

WinVest Acquisition Deal Termination with Embed Financial Group Holdings

Winvest Acquisition Corp. mutually agreed to terminate its previously announced business combination agreement with Embed Financial Group Holdings, effective November 9, 2026. As a result of the termination, the planned merger transactions were abandoned and all related ancillary documents were cancelled. The parties have entered into a mutual release of all claims and liabilities related to the transaction.

Counterparty
Embed Financial Group Holdings
4:31 PM ET 8-K
Leadership Change Algorhythm Holdings, Inc. RIME

Algorhythm Holdings Leadership Change

Ryan J. Smith has transitioned from Chief Operating Officer to Delivery Project Executive as part of an internal restructuring of Azure Energy. As a result of this change in responsibilities, he is no longer considered an executive officer, and the company does not currently intend to appoint a successor COO.

4:31 PM ET Form 4
Insider Selling First Advantage Corp FA

First Advantage Director Slta V (Gp) L.L.C. Sells $324M of Stock

Slta V (Gp) L.L.C., Director, sold 15,000,000 shares of First Advantage Corp at $21.60 a share, worth $324M in total on Nov 12, 2026. Shares held after the trade: 52,846,632 (-22.1%).

Value
$324M
Shares
15,000,000
Price
$21.60
Role
Director
Holding change
-22.1%
Trade date
Nov 12, 2026
4:31 PM ET Form 4
Insider Selling Enova International, Inc. ENVA

Enova International Director Linda Johnson Rice Sells $204K of Stock

Linda Johnson Rice, Director, sold 1,200 shares of Enova International, Inc. at $170.00 a share, worth $204K in total on Nov 11, 2026. Shares held after the trade: 5,077 (-19.1%).

Value
$204K
Shares
1,200
Price
$170.00
Role
Director
Holding change
-19.1%
Trade date
Nov 11, 2026
4:31 PM ET Form 4
Insider Selling Beta Technologies, Inc. BETA

Beta Technologies COO Sean Donovan Sells $651K of Stock

Sean Donovan, COO, sold 23,167 shares of Beta Technologies, Inc. at $28.01 to $28.38 a share (average $28.12) in 2 transactions, worth $651K in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 240,972 (-2.7%).

Value
$651K
Shares
23,167
Average price
$28.12
Role
COO
Holding change
-2.7%
Trade date
Nov 10, 2026 to Nov 11, 2026
4:31 PM ET Form 4
Insider Selling Intercontinental Exchange, Inc. ICE

Intercontinental Exchange CTO Mayur Kapani Sells $765K of Stock

Mayur Kapani, CTO, sold 4,272 shares of Intercontinental Exchange, Inc. at $176.90 to $180.31 a share (average $179.05) in 4 transactions, worth $765K in total on Nov 11, 2026. Shares held after the trade: 69,480 (-0.8%).

Value
$765K
Shares
4,272
Average price
$179.05
Role
CTO
Holding change
-0.8%
Trade date
Nov 11, 2026
4:31 PM ET Form 4
Insider Selling Corcept Therapeutics Inc CORT

Corcept Therapeutics Director Daniel N. Swisher Jr. Sells $111K of Stock

Daniel N. Swisher Jr., Director, sold 1,500 shares of Corcept Therapeutics Inc at $74.07 a share, worth $111K in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).

Value
$111K
Shares
1,500
Price
$74.07
Role
Director
Holding change
-100.0%
Trade date
Nov 10, 2026
4:31 PM ET 8-K
Financial Results IRulya Therapeutics Inc. IRLA

IRulya Therapeutics Financial Results

IRulya Therapeutics (formerly Quince Therapeutics) reported Q3 2026 financial results and provided a corporate update following its recent rebranding and leadership appointments. The company ended the quarter with $105.2 million in cash, which is expected to fund operations through 2028, supporting Phase 2 clinical readouts for its lead candidate LAM-001 in pulmonary diseases.

Term
Q3 2026

“This has been a transformative quarter for our company as we relaunched with a new name and sharpened focus on LAM-001, a potentially first in class inhaled formulation of rapamycin for serious pulmonary diseases. By targeting the mTOR pathway directly in the lungs, LAM-001 holds promise as a potentially disease modifying intervention designed to simultaneously minimize systemic exposure and side effects in these conditions. With a cash runway sufficient to deliver Phase 2 clinical results from multiple indications, we believe IRulya is in a great position to realize LAM-001’s potential.”

Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics
4:31 PM ET 10-Q
Financial Results TPG Private Equity Opportunities, L.P.

TPG Private Equity Opportunities Q3 2026 Results: Net Income $94M, Up 165.1% YoY

TPG Private Equity Opportunities, L.P. is an emerging growth company that invests primarily through the T-POP US Aggregator (CYM), L.P. As of November 10, 2026, the fund had approximately 62.3 million limited partnership units outstanding across seven different classes, including Class I and Class R-S as the largest components.

Key figure
Net income $94M · +165.1% YoY
4:30 PM ET Form 4
Insider Buying Four Corners Property Trust, Inc. FCPT

Four Corners Property Trust President and CEO William H. Lenehan Buys $150K of Stock

William H. Lenehan, President and CEO, bought 6,468 shares of Four Corners Property Trust, Inc. at $23.19 a share, worth $150K in total on Nov 13, 2026. Shares held after the trade: 796,325 (+0.8%).

Value
$150K
Shares
6,468
Price
$23.19
Role
President and CEO
Holding change
+0.8%
Trade date
Nov 13, 2026
4:30 PM ET Form 4
Insider Selling Genius Sports Ltd GENI

Genius Sports Chief Commercial Officer Jack Davison Sells $184K of Stock

Jack Davison, Chief Commercial Officer, sold 30,000 shares of Genius Sports Ltd at $6.14 a share, worth $184K in total on Nov 12, 2026. Shares held after the trade: 1,999,706 (-1.5%).

Value
$184K
Shares
30,000
Price
$6.14
Role
Chief Commercial Officer
Holding change
-1.5%
Trade date
Nov 12, 2026
4:30 PM ET 10-Q
Financial Results Evernorth Holdings Inc. XRPN

Evernorth Holdings Q3 2026 Results: Turns Profitable, Net Income $155M

Evernorth Holdings Inc. reported its third-quarter 2026 financial results, highlighting continued growth in its pharmacy benefit management and specialty pharmacy segments. The filing indicates a focus on expanding specialty pharmacy capabilities and managing medical cost trends effectively while maintaining stable full-year guidance.

Key figure
Net income $155M
4:30 PM ET 8-K
Stock Buyback Boston Omaha Corp BOC

Boston Omaha Announces $85M Stock Buyback

Boston Omaha Corporation's Board of Directors has voted to significantly increase its share repurchase program from $30 million to $85 million. The program allows for repurchases of Class A common stock through open market or private transactions and is set to expire on December 31, 2027. The company intends to fund the buybacks using available cash and cash equivalents.

Value
$85M
Term
through Dec 2027

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.